Crystal structures of ASK1-inhibtor complexes provide a platform for structure-based drug design

Protein Sci. 2013 Aug;22(8):1071-7. doi: 10.1002/pro.2298. Epub 2013 Jul 3.

Abstract

ASK1, a member of the MAPK Kinase Kinase family of proteins has been shown to play a key role in cancer, neurodegeneration and cardiovascular diseases and is emerging as a possible drug target. Here we describe a 'replacement-soaking' method that has enabled the high-throughput X-ray structure determination of ASK1/ligand complexes. Comparison of the X-ray structures of five ASK1/ligand complexes from 3 different chemotypes illustrates that the ASK1 ATP binding site is able to accommodate a range of chemical diversity and different binding modes. The replacement-soaking system is also able to tolerate some protein flexibility. This crystal system provides a robust platform for ASK1/ligand structure determination and future structure based drug design.

Keywords: ASK1; apoptosis signal regulating kinase 1; structure base drug design.

MeSH terms

  • Binding Sites
  • Cardiovascular Diseases / drug therapy
  • Crystallography, X-Ray
  • Drug Design
  • Humans
  • Ligands
  • MAP Kinase Kinase Kinase 5 / antagonists & inhibitors*
  • MAP Kinase Kinase Kinase 5 / chemistry*
  • MAP Kinase Kinase Kinase 5 / genetics
  • MAP Kinase Kinase Kinase 5 / metabolism
  • Neoplasms / drug therapy
  • Neurodegenerative Diseases / drug therapy
  • Sf9 Cells
  • Signal Transduction
  • Staurosporine / chemistry*

Substances

  • Ligands
  • MAP Kinase Kinase Kinase 5
  • MAP3K5 protein, human
  • Staurosporine